echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > China's cell therapy field of blue sea is now far from the world's leading way.

    China's cell therapy field of blue sea is now far from the world's leading way.

    • Last Update: 2020-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, cell therapy research and development is in full swing, according to the new drug research and development monitoring database (CPM) shows that up to now, China's stem cell therapy research projects accounted for about 10% of the world, immunocellular therapy clinical research accounted for about 1/3 of the world, has become the second largest market after the United Statesexpects the FDA to approve 40 to 60 cell and gene therapies by 2030 aloneAt the same time, with the continuous increase in scientific research investment and the strengthening of technical strength, the clinical research on cell and gene therapy in China is increasing year by year, with the number of new additions to the United StatesChina, has become one of the most active areas of cell therapy clinical research in the world"In the past, the struggle between humans and tumors was mainly through surgery, chemotherapy, radiotherapy and other means, " said DrFu Dazhao, director of the Shanghai Biopharmaceutical Science and Technology Industry Promotion Center,CAR-Tbut now, driven by technological progress, health needs, economic development and other factors, humans have ushered in a fourth treatment opportunity - cell therapy, and the future pharmaceutical industry must be the era of cell therapy" cell therapy will become the next medical star Cell therapy is in recent years in the field of medicine", but also one of the most promising research directions, about it has been written mythsearlier, in 2012, emily Whitehead, a six-year-old girl diagnosed with acute lymphoblastic leukemia, became the world's first child to undergo experimental CAR-T therapy at the end of her lifethis case became the most classic case of cell therapy, car-T therapy, and one of the original motivations for subsequent RESEARCH on CAR-T therapy, inspired by this case, the researchers firmly believe that the occurrence of cancer disease will close the door to human survival, but the arrival of cell therapy, especially CAR-T therapy, will open another sunny window for the worldin recent years, cell therapy has also been a hit, especially in the field of cancer treatment has made unprecedented breakthroughs, CAR-T therapy as a different from traditional drugs, as the pharmaceutical giant Novartis CAR-T drug Kymriah and Gilead through the acquisition of Kite's CAR-T therapy Yescarta has been approved, CAR-T therapy has become the most popular cell therapy, but also known in the industry as "CAR-T New Year." according to the, for the treatment of recurrent or refractive children, adolescents (2-25 years) B-cell acute lymphoblastic leukemia (ALL), the product is called Kymriah, Novartis priced $475,000 per treatmentYescarta, which treats patients with large B-cell lymphoma in adults who are unresponsive or recurrent after receiving at least two other treatments and a specific type of non-Hodgkin lymphoma, is listed in the U.Sfor $373,000According to theDrug Comprehensive Database (PDB), Yescarta's sales in 2019 were $456 million, up 73 percent from a year earlier, while Kymriah's sales in 2019 were $278 million, up 266 percent from a year earliersee these two drugs to write a tantalizing market application prospects, gradually, many Chinese pharmaceutical companies have entered the CAR-T therapy layoutglobal, China's cell immunotherapy enterprises engaged in a variety of cell therapy research and developmenthalf of top 10 companies funding cell immunotherapy have two or more cell immunotherapy, CAR-T, TCR-T and NK cell therapy are the research and development directions of the two doors80 cell immunotherapy enterprises, 56 enterprises engaged in CAR-T research and development, accounting for 75%, 15 enterprises engaged in TCR-T research and development, accounting for 20%, 15 enterprises engaged in CAR-NK research and development, accounting for 20%, TIL and CAR-NK, DC cell therapy research and development enterprises are also among the bestcell therapy China market layout difficult as a new immunotherapy has become the focus and hot spot of global cancer therapy research, there is no doubt that CAR-T cell therapy is the next flavor of the erabut unfortunately, there are not many athletes on the CAR-T track at the moment" after the launch of the two products, although there has been some growth in sales, but did not meet expectationson the one hand, may be related to its market pricing, on the other hand, new cell therapy products after the market needs market adaptation, such as clinical use of doctors feedback, product follow-up evaluation tracking process, a variety of treatment methods to compare the evaluation, which also leads to, from a commercial point of view, the future of the cell therapy industry is broad, but this road is very tortuous," said DrFuNot only that, but there are still many gaps between the layout of Chinese pharmaceutical companies in the cell therapy market compared with those of the United Statesspecifically: First, basic research U.Stumor immunoastic basic research originality is very high, and China is relatively lacking, especially lack of innovative research with clinical transformation potential; Third, clinical equipment U.S clinical equipment is relatively complete, diverse, more constructive, China because of the relatively late start, clinical equipment design is relatively simple; Fourth, clinical talent and team building the United States has excellent cell therapy clinical scientists and more mature professional medical team, but China is precisely lack of such talent, which also makes clinical research operability is poor; However, China's cell therapy policy has undergone many changes, until 2016 NMPA gradually established the mechanism for cell therapy to accept and approve drugs in addition, under the current two-track system management, China's CAR-T cell preparation and quality control gap with international giants is still large; but most of China's clinical institutions or hospitals lead, the role of pharmaceutical companies is mainly to support or provide viruses, under this model is difficult to effectively encourage domestic enterprises to participate in THE industrialization of CAR-T therapy , then, subject to the above-mentioned multi-factor constraints, at present, China's only four pharmaceutical companies in the cell therapy layout is mainly based on international cooperation - Kite Pharma and Shanghai Fosun Pharma, Juno Therapeutics and Shanghai Pharmaceutical Sining Juno, Novartis and Shanghai Xibiman, Nanjing Legend and Johnson and Johnson, in order to promote the commercialization of CAR-T products in China in fact, such a model has also been recognized by the market , using Nanjing Legendary Bioas as an example, established a partnership with Johnson and Johnson, and on June 6, 2020, the Company is in the U.S NASDAQ Capital Markets, is currently fully promoting the rapid commercialization of the car-T drug LCAR-B38M/JNJ-4528 global clinical trial, and plans to submit to the FDA in the second half of 2020 JNJ-4528 for the treatment of multiple myeloma biological products licensing application multi-help to break the cell therapy for companies that want to lay out cell therapy in China, there are undoubtedly many challenges especially under the normal state of advanced technology may be in the policy and regulation of the implementation of the more lag, and only to solve this problem, advanced technology can really play its maximum role for patients Dr Fan Xiaohu, chief scientific officer of Nanjing Legendary Biotech Company, believes that at present, the layout of Cell Therapy in China's pharmaceutical companies, the main short board is mainly reflected in downstream construction, and only all enterprises and institutions are involved in the real realization of all-round cooperation between industry, science and research, the whole industry can achieve standardized development "a truly innovative drug that can improve the cure rate of patients should not be in any way hindered in the commercial development path, we must pool multi-resources to effectively promote its commercial production and operation, to achieve the ultimate goal of curing and saving people." in addition, cell therapy research and development enterprises, only combing and perfecting the downstream channels, upstream reagents, supplies, equipment providers can also be smooth development ," Dr Fan Said in fact, according to Pharma-Geographic, at present, China's relevant functional departments on the cell therapy support policy has been constantly improving for example, on March 29, 2019, the National Health and Health Commission issued an example on soliciting the Measures for the Management of Clinical Research and Conversion Applications in Somatic Cell Therapy (Trial) (Draft for Comments) (draft for comments), which further clarified that medical institutions, as the subject of responsibility, conduct clinical research on new technologies such as somatic cell therapy, and obtain safety effectiveness data, can apply for clinical application and charges the document is concerned about the cost of research and development for medical institutions and the cost of patients, the future of somatic cell treatment regulators is also a matter of concern another important industry policy is the "Technical Guidelines for Clinical Trials of Immunocellular Therapeutics Products " (Draft for Comments) issued by CDE on July 6, with a view to providing more targeted advice and guidelines for applicants for drug research and development and research conducting clinical trials of drugs, and various policies are also actively contributing to the development of the cell therapy industry in addition to the policy of the promotion, the local action is also spared no effort On May 26 this year, the held a signing ceremony for key industrial projects in Zhuhai Zhuhai city will vigorously introduce and nurture innovative and competitive high-quality enterprises in the field of health focus on research and development and production of high-end medical devices and innovative drugs, plans to invest a total of 2 billion yuan, introduce Internet intelligent management concepts and eco-building standards, build an accelerated base for the biopharmaceutical industry, build an investment incubation platform for the medical industry, and focus on the introduction of bio-innovative drugs (such as genetically engineered drugs, cell therapy drugs, active proteins and peptide drugs and new drug preparations) and other industries has experienced decades of setbacks and precipitation, cell therapy field in CAR-T, TCR-T, TIL, NK, DC and other breakthrough research progress and with more and more domestic pharmaceutical enterprises stationed in this field, but also face many challenges stand at the forefront of industrial technology, how should China's pharmaceutical enterprises choose the track? How should the field of cell therapy develop in China?
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.